Skip to content

Effects of the Combination of L-Arabinose and Indigestible Dextrin on Obesity

Effects of the Combination of L-Arabinose and Indigestible Dextrin on Obesity: a Double-Blind, Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00880646
Enrollment
70
Registered
2009-04-14
Start date
2009-03-31
Completion date
2009-10-31
Last updated
2009-10-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Brief summary

This study aims to investigate the effect of supplement containing L-arabinose and indigestible dextrin on body mass index, body fat mass, abdominal circumference, visceral fat mass, and serum biochemical parameters in overweight subjects.

Interventions

DIETARY_SUPPLEMENTOolong tea containing L-arabinose and indigestible dextrin
DIETARY_SUPPLEMENTOolong tea (Placebo)

Sponsors

Unitika Ltd.
CollaboratorINDUSTRY
Hiroshima University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy as based on medical history and physical examination * BMI between 25 and 30 kg/m2 * Willing not to serve as blood donor during the study * Informed consent signed

Exclusion criteria

* Female subjects who are pregnant or nursing a child * Participation in any clinical trial up to 90 days before Day 01 of this study * Renal or hepatic dysfunction * Heart disease * Under medication * Subjects who are taking functional food designed for weight loss or serum lipid reduction

Design outcomes

Primary

MeasureTime frame
Body mass index20 weeks

Secondary

MeasureTime frame
Abdominal circumferenceEvery 4 weeks (Overall 20 weeks)
Visceral fat area by CT scanWeek 0, Week 12
Serum lipid profileEvery 4 weeks (Overall 20 weeks)
Body fat massEvery 4 weeks (Overall 20 weeks)
Fasting serum glucose and HbA1c levelsEvery 4 weeks (Overall 20 weeks)
Frequency of bowel movement20 weeks
Serum adiponectin and leptin levelsWeek 0, Week 12

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026